Aktie A14Y0H ACURA PHARMACEUTICALS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Acura Pharmaceuticals, Inc.

Aktien

A14Y0H

US00509L8028

ACUR

Markt geschlossen - OTC Markets
Andere Börsenplätze
 17:03:52 04.06.2024 		% 5 Tage % 1. Jan.
0,0275 USD +175,00 % Intraday Chart für Acura Pharmaceuticals, Inc. 0,00 % +27 400,00 %
04.06. Acura Pharmaceuticals, Inc. und Acura Pharmaceutical Technologies, Inc. geben Veränderungen in der Geschäftsführung bekannt CI
26.03. Acura Pharmaceuticals, Inc. kündigt Änderung der Vereinbarung mit Abuse Deterrent Pharma, LLC an CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Acura Pharmaceuticals, Inc. and Acura Pharmaceutical Technologies, Inc Announce Executive Changes
Acura Pharmaceuticals, Inc. and Acura Pharmaceutical Technologies, Inc Announces CFO Changes
Acura Pharmaceuticals, Inc. announced that it has received $0.2 million in funding
Acura Pharmaceuticals : TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT - Form 8-K
Acura Pharmaceuticals, Inc. Announces Amendment to the Agreement with Abuse Deterrent Pharma, LLC
Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding from Abuse Deterrent Pharma, LLC
Acura Pharmaceuticals, Inc. Receives $250,000 Loan from Abuse Deterrent Pharma, LLC
Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding
Acura Pharmaceuticals : AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSORY NOTE - Form 8-K
Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharmaceuticals, LLC Enter into Amendment #1 to the November 10, 2022 Amended, Consolidated and Restated Secured Promissory Note
Acura Pharmaceuticals : New Financial Obligation - Form 8-K
Acura Pharmaceuticals, Inc. Announces Retirement and Resignation of Mr. Bruce F. Wesson as Member of Board of Directors
Acura Pharmaceuticals, Inc. Provides Update Related to LTX-03 (Hydrocodone Bitartrate and Acetaminophen) Tablets
Acura Pharmaceuticals, Inc. Announces Preliminary Topline Results from Study AP-LTX-311 Successfully Demonstrated That A Nine-Tablet Dose of Ltx-03
Acura Pharmaceuticals : Termination of Material Agreement - Form 8-K
Acura Pharmaceuticals, Inc. and Zyla Life Sciences, LLC Agree to Terms for the Termination of the Collaboration and License Agreement
Acura Pharmaceuticals, Inc. Receives $250,000 Loan from Abuse Deterrent Pharma, LLC
Acura Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
Acura Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021
Acura Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A14Y0H Aktie
  4. Nachrichten Acura Pharmaceuticals, Inc.
  5. Andere Sprachen